MN rgp120/HIV-1 in Alum adjuvant
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for MN rgp120/HIV-1 in Alum adjuvant, covering 2021-11-04 to 2021-11-04. Get the full timeline:
Most recent: Clinical Trial Update: A Phase II Clinical Trial to Evaluate the Immunogenicity and Reactogenicity of the Recombinant HIV-1 Envelope Vaccines SF-2 rgp120 (CHO) [Chiron Vaccines] in MF59 Adjuvant and MN rgp120/HIV-1 [VaxGen] in Alum Adjuvant in Healthy Adults [Phase 2]